Benjamin Helmold, George Nathaniel, Paul Barkhaus, Tulio Bertorini, Mark Bromberg, Andrew Brown, Gregory T Carter, Vincent Chang, Jesse Crayle, Keelie Denson, Jonathan Glass, Terry Heiman-Patterson, Esther Hobson, Carlayne Jackson, Sartaj Jhooty, Elise Mallon, Nicholas Maragakis, Javier Mascias Cadavid, Christopher Mcdermott, Gary Pattee, Kaitlyn Pierce, Olivia Wang, Paul Wicks, Richard Bedlack
{"title":"ALSUntangled #78: Zinc.","authors":"Benjamin Helmold, George Nathaniel, Paul Barkhaus, Tulio Bertorini, Mark Bromberg, Andrew Brown, Gregory T Carter, Vincent Chang, Jesse Crayle, Keelie Denson, Jonathan Glass, Terry Heiman-Patterson, Esther Hobson, Carlayne Jackson, Sartaj Jhooty, Elise Mallon, Nicholas Maragakis, Javier Mascias Cadavid, Christopher Mcdermott, Gary Pattee, Kaitlyn Pierce, Olivia Wang, Paul Wicks, Richard Bedlack","doi":"10.1080/21678421.2025.2476688","DOIUrl":null,"url":null,"abstract":"<p><p>ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). In this review, we assess the utilization of dietary zinc supplements for modulating ALS pathology and progression. Studies in mouse models of ALS have demonstrated that high-dose zinc supplementation may be harmful, but moderate doses could potentially be beneficial. Clinical data is limited, and only one trial has explored zinc supplementation within PALS. This study reported potential benefits in slowing ALS progression but lacked statistical analyses and failed to report quantitative evidence. Numerous case reports from individual patients at varying doses have demonstrated no benefit. Zinc supplements at moderate doses are generally low cost and not associated with severe complications, but further research is required to determine the safety and efficacy of zinc supplementation within PALS. Therefore, we cannot at this time, endorse zinc supplementation to slow ALS progression.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":" ","pages":"599-603"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2025.2476688","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). In this review, we assess the utilization of dietary zinc supplements for modulating ALS pathology and progression. Studies in mouse models of ALS have demonstrated that high-dose zinc supplementation may be harmful, but moderate doses could potentially be beneficial. Clinical data is limited, and only one trial has explored zinc supplementation within PALS. This study reported potential benefits in slowing ALS progression but lacked statistical analyses and failed to report quantitative evidence. Numerous case reports from individual patients at varying doses have demonstrated no benefit. Zinc supplements at moderate doses are generally low cost and not associated with severe complications, but further research is required to determine the safety and efficacy of zinc supplementation within PALS. Therefore, we cannot at this time, endorse zinc supplementation to slow ALS progression.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
